NewLink Genetics Corporation (NLNK) : 6 Wall Street analysts covering NewLink Genetics Corporation (NLNK) believe that the average level the stock could reach for the short term is $17.83. The maximum price target given is $23 and the minimum target for short term is around $10, hence the standard deviation is calculated at $5.46.
NewLink Genetics Corporation (NLNK) : 6 analysts are covering NewLink Genetics Corporation (NLNK) and their average rating on the stock is 1.67, which is read as a Buy. 4 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. A total of 2 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.
Also, Equity Analysts at the Brokerage Firm, Stifel Nicolaus, maintains their rating on the shares of NewLink Genetics Corporation (NASDAQ:NLNK). Stifel Nicolaus has a Buy rating on the shares. As per the latest research report, the brokerage house lowers the price target to $22 per share from a prior target of $23. The rating by the firm was issued on August 1, 2016.
NewLink Genetics Corporation (NASDAQ:NLNK): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $10.24 and $10.07 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $10.34. The buying momentum continued till the end and the stock did not give up its gains. It closed at $10.31, notching a gain of 1.28% for the day. The total traded volume was 203,178 . The stock had closed at $10.18 on the previous day.
NewLink Genetics Corporation (NewLink) is a biopharmaceutical company focused on discovering, developing and commercializing immunotherapeutic products for cancer treatment. Its portfolio includes both biologic and small-molecule immunotherapy product candidates. Its biologic product candidates are based on its HyperAcute immunotherapy technology, which is designed to stimulate the human immune system. Its small-molecule product candidates are focused on breaking the immune systems tolerance to cancer by inhibiting the indoleamine-(2, 3)-dioxygenase (IDO) pathway. Its lead product candidate algenpantucel-L or HyperAcute Pancreas. HyperAcute Pancreas is being studied in two Phase III clinical trials; one in surgically-resected pancreatic cancer patients that is being performed under a Special Protocol Assessment (SPA) with the United States Food and Drug Administration (FDA) and one in patients with locally advanced pancreatic cancer.